Edwards Lifesciences to Sell Critical Care to BD
Edwards Lifesciences announced the sale of its Critical Care product group to BD (Becton, Dickinson and Company) for $4.2 billion in cash. The transaction will enhance Edwards' financial flexibility and enable strategic investments in structural heart disease technologies. The deal is expected to close by the end of 2024, pending regulatory approvals. Edwards aims to focus on advancing innovations in aortic, mitral, tricuspid, and pulmonic treatments. The sale is anticipated to have an immaterial impact on adjusted EPS in 2024.
- Sale of Critical Care group for $4.2 billion in cash.
- Enhances financial flexibility for strategic growth investments.
- Focus on advancing aortic, mitral, tricuspid, and pulmonic technologies.
- Transaction is expected to close by the end of 2024.
- Positioning for sustainable growth and increased shareholder value.
- Immaterial impact on adjusted EPS in 2024.
- Pending regulatory approvals could delay the transaction.
Edwards Lifesciences has announced the sale of its Critical Care product group to BD for
From a financial standpoint, the infusion of cash will likely bolster Edwards' balance sheet, enabling it to make disciplined investments in new technologies and therapeutic areas. The transaction is expected to have an immaterial impact on adjusted earnings per share (EPS) for 2024. However, the long-term implications could include enhanced shareholder value through increased focus on high-growth areas.
Investors should note the shift in company strategy and how it aligns with long-term growth ambitions. The sale also suggests a managed approach toward capital allocation, potentially leading to improved returns on investment. Given the scale of the deal and its alignment with Edwards' strategic goals, it's a prudent move for both short-term stability and long-term growth.
Edwards' decision to sell its Critical Care segment to BD underscores its commitment to advancing structural heart disease innovations. This focus is important given the increasing prevalence of cardiac conditions and the growing demand for advanced therapeutic options. By concentrating resources on aortic, mitral, tricuspid and pulmonic valve technologies, Edwards is positioning itself as a leader in this specialized field.
The reinvestment of proceeds into new therapeutic areas such as interventional heart failure could lead to expanded treatment options and improved patient outcomes. This strategic pivot is likely to enhance Edwards' clinical capabilities and strengthen its competitive edge in the cardiology market.
This move aligns with industry trends favoring specialized, high-impact innovations over broader, less differentiated portfolios. For investors, this could signify increased long-term value driven by a sharper focus on high-growth, high-demand medical technologies.
The sale of Edwards' Critical Care product group to BD represents a strategic realignment that could significantly impact the market landscape. By divesting this segment, Edwards can channel resources into its structural heart disease portfolio, which includes groundbreaking technologies like transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid innovations. This focus is in line with market needs, as there is a strong demand for advanced cardiac solutions driven by aging populations and rising cardiovascular diseases.
From a market perspective, this transaction could lead to increased market share for Edwards in the structural heart domain. For BD, the acquisition enhances its critical care offerings, potentially boosting its competitive positioning in the broader healthcare market. Both companies stand to benefit, which could positively impact their respective stock performances.
The strategic intent behind this deal aligns with Edwards' goal of serving large unmet patient needs and extending its global leadership. For retail investors, this represents a solid move towards sustainable growth and increased shareholder value.
Agreement strengthens Edwards’ strategy to advance structural heart innovation
Edwards will use the after-tax cash proceeds to fund strategic growth investments. The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure. Edwards’ goal is to build the most comprehensive structural heart disease portfolio through its pursuit of breakthrough technologies, indication expansions and world-class evidence for its surgical, TAVR and transcatheter mitral and tricuspid innovations, with the focus on helping even more patients around the world.
“Edwards’ underlying rationale for separating Critical Care remains the same: we are laser focused on pursuing a strategy centered on structural heart disease,” said Bernard Zovighian, Edwards’ CEO. “Our goal is to serve large unmet patient needs with our differentiated innovations while extending our global leadership, delivering sustainable growth and increasing shareholder value. Critical Care has made significant contributions to our company and has a long history of pioneering innovation. We believe this transaction will strengthen Edwards, Critical Care and BD, paving the way for both companies to deliver even greater value to patients.”
Critical Care will operate in
The transaction is expected to close by the end of 2024, subject to the satisfaction or waiver of certain closing conditions, including the receipt of required antitrust and foreign investment approvals. If it closes as expected, the impact to adjusted earnings per share (EPS) in 2024 would be immaterial. Other terms of the agreement were not disclosed.
Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC served as financial advisors, and Skadden Arps served as legal counsel to Edwards on the transaction.
About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit www.edwards.com and follow us on Facebook, Instagram, LinkedIn, X and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements made by Mr. Zovighian, statements regarding the delivery of additional value for patients and Edwards’ goals in structural heart innovation, the timing for the closing of the transaction and Edwards’ ability to satisfy the closing conditions, including the receipt of required antitrust and foreign investment approvals. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include, but are not limited to: (i) Edwards and BD may be unable to close the transaction in a timely manner or at all, including obtaining required regulatory approvals and satisfying other closing conditions, which may materially and adversely affect Edwards’ business and the price of Edwards’ common stock; (ii) uncertainty as to the timing of closing of the transaction; (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the purchase agreement; (iv) risks related to disruption of management’s attention from Edwards’ ongoing business operations; (v) the effect of the announcement or the pendency of the transaction on Edwards’ relationships with its customers, operating results and business generally; (vi) potential significant transaction costs associated with the transaction; (vii) the outcome of any legal proceedings or regulatory actions to the extent initiated against Edwards, BD or others related to the transaction; (viii) the ability of Edwards to execute on its strategy and achieve its goals and other expectations after the closing of the transaction; (ix) legal, regulatory, tax and economic developments affecting Edwards’ business; (x) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, outbreak of war or hostilities or current or future pandemics or epidemics, as well as Edwards’ response to any of the aforementioned factors; and (xi) other risks detailed in Edwards’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. These filings, along with important safety information about our products, may be found at Edwards.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603908185/en/
Media Contact: Amy Hytowitz, 949-250-4009
Investor Contact: Mark Wilterding, 949-250-6826
Source: Edwards Lifesciences Corporation
FAQ
What is the value of the transaction for Edwards Lifesciences' sale to BD?
When is the transaction between Edwards Lifesciences and BD expected to close?
What will Edwards Lifesciences use the proceeds for?
What impact will the transaction have on Edwards Lifesciences' EPS in 2024?
Why is Edwards Lifesciences selling its Critical Care group?
